Curio Wealth LLC Acquires Shares of 1,189 Pfizer Inc. (NYSE:PFE)

Curio Wealth LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,189 shares of the biopharmaceutical company’s stock, valued at approximately $32,000.

Other large investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI lifted its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after buying an additional 159,984 shares during the last quarter. Parnassus Investments LLC lifted its position in shares of Pfizer by 3.7% in the 3rd quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company’s stock worth $127,067,000 after buying an additional 156,894 shares during the last quarter. Finally, TrinityPoint Wealth LLC lifted its position in shares of Pfizer by 85.5% in the 3rd quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company’s stock worth $5,543,000 after buying an additional 88,258 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Up 1.3 %

Pfizer stock opened at $26.07 on Tuesday. The stock has a market cap of $147.72 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company’s 50-day moving average price is $26.22 and its two-hundred day moving average price is $27.10. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.